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Abstract
Aims To assess the impact of the lockdown due to coronavirus disease 2019 (COVID-19) on key quality indicators for the 
treatment of ST-segment elevation myocardial infarction (STEMI) patients.
Methods Data were obtained from 41 hospitals participating in the prospective Feedback Intervention and Treatment Times 
in ST-Elevation Myocardial Infarction (FITT-STEMI) study, including 15,800 patients treated for acute STEMI from Janu-
ary 2017 to the end of March 2020.
Results There was a 12.6% decrease in the total number of STEMI patients treated at the peak of the pandemic in March 2020 
as compared to the mean number treated in the March months of the preceding years. This was accompanied by a significant 
difference among the modes of admission to hospitals (p = 0.017) with a particular decline in intra-hospital infarctions and 
transfer patients from other hospitals, while the proportion of patients transported by emergency medical service (EMS) 
remained stable. In EMS-transported patients, predefined quality indicators, such as percentages of pre-hospital ECGs 
(both 97%, 95% CI = − 2.2–2.7, p = 0.846), direct transports from the scene to the catheterization laboratory bypassing the 
emergency department (68% vs. 66%, 95% CI = − 4.9–7.9, p = 0.641), and contact-to-balloon-times of less than or equal to 
90 min (58.3% vs. 57.8%, 95%CI = − 6.2–7.2, p = 0.879) were not significantly altered during the COVID-19 crisis, as was 
in-hospital mortality (9.2% vs. 8.5%, 95% CI = − 3.2–4.5, p = 0.739).
Conclusions Clinically important indicators for STEMI management were unaffected at the peak of COVID-19, suggesting 
that the pre-existing logistic structure in the regional STEMI networks preserved high-quality standards even when chal-
lenged by a threatening pandemic.
Clinical trial registration NCT00794001
Keywords ST-segment elevation myocardial infarction (STEMI) · Percutaneous coronary intervention (PCI) · Key quality 
indicators · Contact-to-balloon time · Mortality · COVID-19
Introduction
According to a well-established recommendation in the cur-
rent guidelines, patients presenting with ST-segment eleva-
tion myocardial infarction (STEMI) require instant revas-
cularization by percutaneous coronary intervention (PCI), 
since any time delay in treatment is associated with increased 
cardiac damage and elevated mortality [1]. Given the overall 
high morbidity and mortality in STEMI patients, systems of 
STEMI care have been established to expedite PCI work-
flows to minimize the ischaemic time from symptom onset to 
balloon inflation during PCI. As shown recently, predefined 
key quality indicators for STEMI care have remained stable 
over the last decade having been successfully implemented 
in local STEMI care networks before being challenged by a 
globally occurring crisis [2]. However, the extent to which 
a pandemic like the currently ongoing corona virus disease 
19 (COVID-19) affects the health care system for STEMI 
treatment is largely unknown [3, 4]. Due to the rapid spread 
of the corona virus across the globe since its initial out-
break in Wuhan, China, in December 2019, the pandemic 
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has placed enormous strain on nearly all healthcare systems 
worldwide [5–7]. Since most countries confronted with the 
novel betacoronavirus SARS-CoV-2 implemented stringent 
infection control measures, these restrictions may have a 
profound impact on routine medical care and, in particular, 
STEMI management [3, 4, 7–15]. In this paper, we assess 
the impact of the global COVID-19-induced lockdown on 
STEMI care with a particular focus on key quality indica-
tors using data from the ongoing, multicentre, prospective 
Feedback Intervention and Treatment Times in ST-Elevation 
Myocardial Infarction (FITT-STEMI) study.
Methods
Design of the FITT‑STEMI study
The FITT-STEMI trial, which currently recruits more than 
10% of all STEMI cases in Germany [16], was initially 
designed to prospectively assess the prognostic benefit of 
systematic and formalized data assessment and interactive 
feedback on time to interventional treatment for patients pre-
senting with STEMI. The primary aim of the FITT-STEMI 
study, registered at clinicaltrials.gov under the number 
NCT00794001, was to implement standardized feedback-
driven quality management for timely reperfusion therapy in 
existing regional STEMI care networks. The study protocol 
was approved by the ethics committee of the Medical Fac-
ulty at the University of Göttingen (1/10/07) and by the local 
ethics committee of each participating PCI centre. Details 
on the study design, data collection, and outcome measures 
including first clinical results have been described [17, 18].
Data assessment and outcome measures
The participating 41 PCI hospitals are all tertiary care cen-
tres included seven university clinics. All centres collected 
detailed clinical information for each consecutive STEMI 
patient on treatment times, including time intervals from 
symptom onset to arrival of the emergency medical service 
(EMS) on the scene, the duration of out-of-hospital treat-
ment and the transport time to the nearest PCI centre as 
well as intra-hospital times for the transfer to the catheteri-
zation laboratory and the time to balloon inflation. In addi-
tion, comorbid diagnoses, medical history, Thrombolysis in 
Myocardial Infarction (TIMI) risk score for STEMI [19], 
medical history, cardiac risk factors, and results from coro-
nary angiography as well as the PCI procedure were docu-
mented on a case-report form. The following predefined key 
quality data for STEMI management were obtained: percent-
ages of pre-hospital ECG recordings, pre-announcement of 
STEMI diagnosis by telephone before arrival at the hospital, 
direct transfer to the catheterization laboratory bypassing the 
emergency department, and contact-to-balloon time equal or 
less than 90 min.
Statistical analysis
For this post hoc study of the influence of the COVID-
19-induced lockdown on German regional STEMI care net-
works, raw data from January 2017 to inclusively March 
2020 were analyzed. Descriptive statistics were calculated 
as means with standard errors of the mean for continuous 
variables and frequencies with percentages for categorical 
variables. Continuous data were compared using Student´s 
t test between the two groups of patients treated in March 
2020 versus the three March months in the preceding years 
2017–2019. Categorical variables from these two groups 
were analyzed using chi-square tests. For some of the anal-
yses, the study cohort was classified along the guideline-
recommended threshold for a contact-to-balloon time equal 
or less than 90 min. A series of linear regression models 
were computed with intervals of treatment times as depend-
ent variable and study recruitment in March 2020 during 
the corona virus outbreak versus the March months in the 
three preceding years as independent variable. These models 
were adjusted for gender, age, TIMI risk score, infarct locali-
zation, and thrombolytic therapy. Logistic regression mod-
els for key quality markers in STEMI care as independent, 
dichotomous variables were created using the same set of 
covariables. In addition, a subgroup analysis was performed 
for all FITT-STEMI clinics in the Lower Rhine area around 
Heinsberg located close to Aachen, because this region in 
North Rhine-Westphalia was most heavily affected by the 
SARS-CoV-2 outbreak. As shown in the catchment area 
maps in Fig. 1, the recruitment of patients to the nation-
wide FITT-STEMI study centres partially overlapped with 
areas of high prevalence of confirmed SARS-CoV-2-positive 
cases, specifically at the Lower Rhine area. Statistical analy-
ses were performed using the SAS system (version 9.4). All 
reported p values are two-sided, and p values < 0.05 were 
considered statistically significant. No formal adjustment for 
multiple testing was carried out.
Results
Number of STEMI patients during the peak 
COVID‑19 lockdown
In total, 15,800 consecutive STEMI patients presenting 
within 24 h of symptom onset were treated from January 1, 
2017, to March 31, 2020 in all participating centres of the 
FITT-STEMI study group. Of those, the majority of patients 
(n = 12,070, 76.4%) were transported directly from the field 
to the PCI hospital by EMS (Table 1). Transfers from other, 
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non-PCI-capable hospitals to FITT-STEMI clinics consti-
tuted the second largest group with 1733 patients (11.0%), 
which was followed by the group of STEMI patients arriv-
ing at hospitals independently as self-referrals (n = 1598; 
10.1%). During the total study period starting from January 
2017, the average number of patients treated monthly who 
had a documented myocardial infarction experienced during 
hospital stay was ten patients (2.5%). Among all STEMI 
patients treated, 122 patients had pre-PCI fibrinolysis 
(0.8%) and 14,186 patients received primary PCI (89.8%). A 
detailed description of the total study population, including 
the comparison between the two groups of STEMI patients 
treated in March 2020 and the preceding three March months 
in the years 2017–2019, is given in Table 1.
Altered admission modes at the peak 
of the COVID‑19 crisis
When the COVID-19 crisis peaked in Germany in March 
2020, there were 387 documented STEMI cases treated in 
the centres of the FITT-STEMI cluster, which corresponds 
to a decline of 12.6% as compared to the March months of 
the previous 3 years (Table 1). In addition, we noted sig-
nificant changes in the distinct transport modes to hospital 
admission (p = 0.017) (Fig. 2a). The most prominent decline 
in the proportion of case numbers was found for STEMI 
patients suffering from in-hospital infarction (2.7% vs. 1.3%) 
followed by patients transported indirectly from external, 
non-PCI-capable centres (12.0% vs. 7.5%), because the 
majority of hospitals had previously discharged all their 
elective patients due to the general shutdown associated 
with the COVID-19 crisis. Likewise, the percentage of 
self-referred STEMI patients was reduced in the last March 
month (9.4% vs. 8.5%), whereas the percentage of patients 
transported directly from the pre-hospital setting to the 
hospital by EMS increased from 75.8% to 82.7% (Fig. 2b). 
Since this group of STEMI patients who called the EMS to 
seek medical help because of ischaemia-induced chest pain 
always constituted the majority of STEMI cases, the total 
number of 387 STEMI patients treated in the March 2020 
during the crisis was only slightly smaller than the monthly 
case number averaged from the March months 2017–2019 
(Fig. 2a).
Stability of key quality indicators for STEMI care 
during the SARS‑CoV‑2 outbreak
The total number of EMS-transported patients treated 
within 360 min after first medical contact was reduced when 
compared to the mean of monthly cases in the preceding 
three March months (n = 270 patients vs. n = 904 patients, 
− 10.4%) (Table 2). When assessing key quality indica-
tors, we found that pre-hospital ECGs were recorded for 
261 of these 270 EMS-transported patients (96.7%, Table 2, 
Fig. 3a). This percentage was stable, when compared to 
the three previous COVID-19-free March months (96.9%, 
95%CI = − 2.2–2.7, p = 0.846). Similarly, the number of 
direct transfers to PCI treatment bypassing the emergency 
department remained at the same high level, as n = 179 
(66.3%) patients reached the catheterization laboratory with-
out a time-consuming delay before the reperfusion therapy. 
In the three preceding March months, the percentage of 
patients arriving at the catheterization laboratory without 
a stop at the emergency department was not significantly 
changed (67.8%, 95% CI = − 4.9–7.9, p = 0.641). In addi-
tion, there was no significant difference in the proportion of 
STEMI patients with treatment times from first medial con-
tact to balloon inflation of equal or less than 90 min (57.8% 
vs. 58.3%, 95%CI = − 6.2–7.2, p = 0.879). Except for longer 
transport times from the field to the hospital (p = 0.003), the 
Fig. 1  Catchment area maps 
showing home postcodes for 
all STEMI patients included 
in the FITT-STEMI study (a) 
and regional hot spots of the 
COVID-19 outbreak during the 
initial phase of the epidemic in 
Germany (b). The maps depict 
the overlap of the two distribu-
tions particularly in the Lower 
Rhine area in North-West 
Germany
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Table 1  Baseline characteristics of the total study cohort of STEMI patients treated from January 2017 to March 2020 in 41 German hospitals 
participating in the FITT-STEMI trial
Total study cohort
(n = 15,800)
Patients included in the March 
months 2017/2018/2019 (n = 1329)
Patients included in 
March 2020 (n = 387)
P value
Demographic data
 Male gender (n = 15,800) 11,558 (73%) 953 (72%) 277 (72%) 0.960
 Age ± SD (years) (mean, SEM) (n = 15,415) 63.9 ± 0.1 63.6 ± 0.4 64.5 ± 0.7 0.226
Transport routes
 EMS 12,070 (76.4%) 1008 (75.8%) 320 (82.7%) 0.017
 Inter-facility transports 1733 (11.0%) 160 (12.0%) 29 (7.5%)
 Self-referral 1598 (10.1%) 125 (9.4%) 33 (8.5%)
 Intra-hospital infarct 399 (2.5%) 36 (2.7%) 5 (1.3%)
Clinical data
 Hypertension 9245 (59%) 791 (60%) 229 (59%) 0.903
 Diabetes mellitus 2842 (18%) 264 (20%) 79 (20%) 0.812
 Previous angina pectoris 1604 (10%) 147 (11%) 31 (8%) 0.083
 Hyperlipidemia 4385 (28%) 372 (28%) 119 (31%) 0.291
 Family history of cardiovascular events 2979 (19%) 225 (17%) 74 (19%) 0.317
 Current smoker 6380 (40%) 523 (39%) 155 (40%) 0.805
 Previous myocardial infarction 1793 (11%) 153 (12%) 47 (12%) 0.733
 Previous stroke 681 (4%) 53 (4%) 17 (4%) 0.723
 Previous angioplasty 1936 (12%) 160 (12%) 58 (15%) 0.125
 Previous CABG 354 (2%) 28 (2%) 10 (3%) 0.575
 Renal failure 779 (5%) 61 (5%) 26 (7%) 0.093
 Out-of-hospital cardiac arrest 1461 (9%) 127 (10%) 41 (11%) 0.545
 Cardiogenic shock 1984 (13%) 169 (13%) 50 (13%) 0.916
 TIMI risk score 3.89 ± 0.02 3.88 ± 0.07 3.87 ± 1.31 0.464
ECG (STEMI site) (n = 15,694)
 Anterior 7044 (45%) 601 (46%) 176 (46%) 0.978
 Inferior 7414 (47%) 603 (46%) 175 (46%)
 Lateral 965 (6%) 83 (6%) 22 (6%)
 LBBB 271 (2%) 32 (2%) 10 (3%)
Thrombolytic therapy (n = 15,800) 122 (0.8%) 10 (0.8%) 3 (0.8%) 0.964
Primary PCI treatment (n = 15,800) 14,186 (89.8%) 1,205 (90.7%) 352 (91.0%) 0.864
Hospital mortality (n = 15,768) 1388 (8.8%) 118 (8.9%) 37 (9.6%) 0.680
Angiographic results
 No. coronary arteries narrowed (n = 15,388)
  0 588 (4%) 47 (4%) 11 (3%) 0.382
  1 5185 (34%) 447 (34%) 129 (35%)
  2 4538 (29%) 367 (28%) 120 (32%)
  3 4981 (32%) 431 (33%) 110 (29%)
  LMCA 96 (0.6%) 5 (0.4%) 3 (0.8%)
 CTO in NIRA (n = 15,733) 1802 (12%) 156 (12%) 44 (11%) 0.829
 Recanalized vessel (n = 14,163)
  LAD 6271 (40%) 541 (45%) 154 (44%) 0.521
  RCA 5685 (36%) 480 (40%) 136 (39%)
  LCX 1939 (12%) 165 (14%) 52 (15%)
  LMCA 179 (1%) 10 (1%) 6 (2%)
  Graft 89 (1%) 8 (1%) 4 (1%)
 TIMI angiographic flow grade before PCI (n = 14,469)
  Score 0–2 13,284 (92%) 1138 (92) 325 (91%) 0.358
  Score 3 1185 (8%) 92 (7%) 32 (9%)
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seven university clinics did not differ from other tertiary 
hospitals with respect to treatment times and quality indica-
tors for STEMI care during the lockdown.
Pre‑ and intra‑hospital treatment 
times during the COVID‑19 crisis
We found no evidence that symptomatic STEMI patient 
waited longer to seek medical help during the virus out-
break for fear of an hospital-acquired infection, as the mean 
time interval from symptom onset to first medical contact 
was not prolonged (163.1 ± 7.9 min vs. 150.4 ± 13.6 min, 
95% CI = − 19.1–44.5, p = 0.433). For all STEMI patients 
transported by EMS and treated within 360 min after first 
medical contact, the mean contact-to-door time in the March 
months from 2017–2019 was 39.9 ± 0.5  min (Table  2, 
Fig. 3). In March 2020, this time interval was in a similar 
range (39.4 ± 1.0 min), indicating that there were no statis-
tically significant and clinically relevant delays during the 
COVID-19 precautions (95% CI = − 1.6–2.7, p = 0.629). 
Likewise, the mean door-to-balloon time was similar in the 
last March month to the three preceding ones (51.3 ± 1.1 min 
vs. 53.2 ± 2.0 min, 95% CI = − 6.3–2.6, p = 0.407) (Fig. 3). 
In all, the treatment times from arrival at the field to bal-
loon inflation during PCI did not significantly differ between 
the two groups (91.3 ± 1.2 min vs. 92.6 ± 2.2 min, 95% 
CI = − 6.2–3.5, p = 0.592). Regression models adjusted 
for gender, age, TIMI risk score, infarct localization, and 
thrombolytic therapy confirmed these results (Supplemental 
Table 1). However, in univariate analysis, there was a small 
but significant difference in the mean times from arrival at 
the catheterization laboratory to vessel puncture between 
patients treated before or during the COVID-19 outbreak 
(12.9 ± 0.3 min vs. 14.1 ± 0.5 min, 95% CI = − 2.3–-0.1, 
p = 0.029).
Revascularization rates and in‑hospital mortality 
during the COVID‑19 crisis
Angiographic results showed a similarly high rate of com-
plete revascularization in patients treated during the outbreak 
of the SARS-CoV-2 infections as compared to the success 
Table 1  (continued)
Total study cohort
(n = 15,800)
Patients included in the March 
months 2017/2018/2019 (n = 1329)
Patients included in 
March 2020 (n = 387)
P value
 TIMI angiographic flow grade after PCI (n = 14,174)
  Score 0–2 876 (6%) 78 (6%) 20 (6%) 0.591
  Score 3 13,298 (94%) 1127 (94%) 332 (94%)
Data are presented as percentages or means and standard errors of the mean for the total study cohort. Angiographic data refer to patients in 
whom an angiogram was performed. A comparison between the subgroups of patients treated in March 2020 at the peak of the COVID-19 crisis 
during the German lockdown and the preceding three March months from 2017 to 2019 is included
CABG coronary artery bypass grafting, CTO chronic total occlusion, ECG electrocardiogram, EMS transport by emergency medical service, 
LAD left anterior descending artery, LBBB left bundle branch block, LCX left circumflex artery, LMCA left main coronary artery, NIRA non-
infarct-related arteries, PCI percutaneous coronary intervention, RCA right coronary artery, SD standard deviation, TIMI Thrombolysis in Myo-
cardial Infarction
Fig. 2  Modes of admission to hospitals for STEMI patients during 
the corona virus crisis. a Total numbers of STEMI patients admit-
ted to PCI hospitals by the indicated modes in March 2020 com-
pared to the March months in the three preceding years 2017–2020. 
b Increased percentage of patients admitted by emergency medical 
service (EMS) during the COVID-19 outbreak in March 2020 as 
compared to the previous March months in 2017–2019, whereas the 
proportion of non-EMS transports was reduced
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rate of reperfusions in the three March months before. As 
measured by a TIMI grade 3 coronary flow, a complete ante-
grade perfusion into the vessel bed distal to the obstruction 
was achieved in more than nine out of ten patients in the two 
groups (93.5% vs. 94.3%, p = 0.591) (Table 1). At the peak 
of the COVID-19 outbreak, the mortality rate did not differ 
from the period before the viral outbreak, neither in the sam-
ple of all STEMI patients (Table 1) nor in the subgroup of 
EMS-transported, PCI-treated patients (Table 2). In March 
2020, there were 23 deaths (8.5%) in EMS-transported 
STEMI patients in whom the PCI procedure was performed 
within 360 min of first medical contact, while there were on 
average 27.7 monthly deaths (9.2%) in the March months of 
the three preceding years (95% CI = − 3.2–4.5, p = 0.739) 
(Table 2, Fig. 3).
Subgroup analysis of clinics heavily affected 
by the SARS‑CoV‑2 outbreak
The Lower Rhine area around Heinsberg in North Rhine-
Westphalia had emerged as a hot spot for the spread of 
the coronavirus with the highest numbers of SARS-CoV-
2-positive cases in Germany, particularly in the initial 
phase of the virus outbreak (Fig. 1). In a subgroup analysis 
of seven FITT-STEMI clinics located in the centre of this 
heavily affected area, we found that four key quality indi-
cators for STEMI care stayed stable and did not deterio-
rate during the course of the infection (Table 3, Fig. 3b). 
The rate of pre-hospital ECG recordings was unaltered, as 
only two out of 35 cases (94.3%) arrived at the PCI hospital 
without an ECG-based diagnosis of myocardial infarction 
compared to nine out of 141 patients in the three previ-
ous March months (93.6%). This difference in the number 
of ECG recordings was not statistically significant (95% 
CI = − 9.4–8.0, p = 0.884). Similarly, neither was the num-
ber of direct transports to the catheterization laboratory 
Table 2  Changes in reported key quality indicators for EMS-transported and PCI-treated STEMI patients who had treatment times from first 
medical contact to balloon inflation of equal to or less than 360 min




Patients treated in the March 
months 2017–2019 (n = 904)
Patients treated in the 





Symptom-to-contact time (min) 
(n = 10,455)
159.1 ± 2.3 163.1 ± 7.9 150.4 ± 13.6 12.7 [− 19.1; 44.5] 0.433
Duration of EMS at scene 
(n = 10,514)
23.1 ± 0.1 23.1 ± 0.4 22.5 ± 0.8 0.6 [− 1.1; 2.3] 0.502
Transport time by EMS 
(n = 10,512)
16.8 ± 0.1 16.7 ± 0.3 17.0 ± 0.6 − 0.2 [− 1.5; 1.0] 0.705
Contact-to-door time (min) 
(n = 10,629)
39.9 ± 0.2 39.9 ± 0.5 39.4 ± 1.0 0.5 [− 1.6; 2.7] 0.629
Door-to-cath time (min) 
(n = 10,608)
19.8 ± 0.3 18.7 ± 0.9 18.9 ± 1.7 − 0.2 [− 4.0; 3.7] 0.925
Cath-to-puncture time (min) 
(n = 10,572)
13.2 ± 0.1 12.9 ± 0.3 14.1 ± 0.5 − 1.2 [− 2.3; − 0.1] 0.029
Puncture-to-balloon (min) 
(n = 10,612)
20.4 ± 0.1 19.7 ± 0.4 20.2 ± 0.8 − 0.47 [− 2.21; 1.27] 0.594
Door-to-balloon time (min) 
(n = 10,629)
53.0 ± 0.3 51.3 ± 1.1 53.2 ± 2.0 − 1.9 [− 6.3; 2.6] 0.407
Contact-to-balloon time (min) 
(n = 10,633)
92.9 ± 0.4 91.3 ± 1.2 92.6 ± 2.2 − 1.3 [− 6.2; 3.5] 0.592
ECG before arrival at the hospital 
(n = 10,633)
10,348 (97%) 876 (97%) 261 (97%) 0.2 [− 2.2; 2.7] 0.846
Pre-announcement by telephone 
(n = 10,633)
9,037 (85%) 774 (86%) 231 (86%) 0.1 [− 4.7; 4.8] 0.979
Emergency department bypass 
(n = 10,633)
7,016 (66%) 613 (68%) 179 (66%) 1.5 [− 4.9; 7.9] 0.641
Contact-to-balloon time ≤ 90 min 
(n = 10,633)
6,235 (58.6%) 527 (58.3%) 156 (57.8%) 0.5 [− 6.2; 7.2] 0.879
Hospital mortality (n = 10,633) 914 (8.6%) 83 (9.2%) 23 (8.5%) 0.7 [− 3.2; 4.5] 0.739
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bypassing the emergency department (60.3% vs. 51.4%, 
95% CI = − 9.6–27.3, p = 0.341) nor the proportion of con-
tact-to-balloon times within 90 min (64.5% vs. 62.9%, 95% 
CI = − 19.5–16.2, p = 0.853) reduced significantly at the 
peak of the coronavirus outbreak. Likewise, the proportion 
of pre-announcement by telephone before the ambulance 
arrived at the hospital did not differ between the groups 
(80.9% vs. 77.1%, 95% CI = − 11.6–19.1, p = 0.623). Except 
for a shorter EMS transport time by 3 min during the lock-
down (15.1 ± 0.7 min vs 12.1 ± 1.2 min, 95% CI = 0.04–5.90, 
p = 0.047), all other measured time intervals did not differ 
when compared for the months with and without infections 
(Table 3, Fig. 4b). 
Discussion
By analysing the impact of the SARS-CoV-2 pandemic on 
STEMI treatment in established networks, we noted four 
important points. Firstly, we found only a mild decrease in 
the absolute number of STEM patients treated in systems of 
STEMI care in Germany (12.6%). Secondly, this decrease 
included STEMI patients with self-referral, transfer patients 
from non-PCI hospitals, and patients suffering myocardial 
infarction during hospital stay, whereas the number of EMS-
transported STEMI cases remained stable. Thirdly, except 
for a significantly prolonged time from arrival at the cathe-
terization laboratory to vessel puncture, there were no signif-
icant changes in parameters of STEMI care and time lines of 
the treatment chain in the group of STEMI patients directly 
brought by EMS to the PCI-hospitals. Fourthly, even in the 
hot spot of SARS-CoV-2 infections during March 2020 in 
the heavily affected Lower Rhine area, which was com-
pletely covered by hospitals involved in the FITT-STEMI 
programme, we found no impairment in the established qual-
ity indicators for STEMI care.
In Germany, STEMI patients transported by EMS from 
the scene constitute the vast majority of acute PCI-treated 
STEMI cases and this number did not decline during the 
virus outbreak. Although the case numbers of patients 
with self-referral or inter-facility transports were remark-
ably reduced, there was only a moderate decrease in total 
STEMI numbers at the peak of the infections. This finding 
is in contrast to three recent reports on decreasing numbers 
of STEMI treatment published from cardiac catheterization 
laboratories in the United States and Spanish PCI centres 
[8, 20, 21].
Notably, in our cohort, there were neither significant 
delays in the contact-to-door nor the door-to-balloon time 
related to the outbreak of the virus. However, owing to safety 
precautions in preparation for the PCI procedure, the time 
interval from arrival at the catheterization laboratory to ves-
sel puncture was significantly prolonged. This observation 
Fig. 3  Percentages of achieved 
key quality indicators for 
STEMI treatment over the 
39-month period from January 
2017 to March 2020 in all 
the 41 participating FITT-
STEMI study centres (a) and 
a subgroup thereof with seven 
centers in the Lower Rhine area 
heavily engaged in fighting the 
SARS-CoV-2 pandemic (b). 
March months are indicated 
by the red letter “M”. The last 
point in each curve corresponds 
to the lockdown month with 
high COVID-19 case numbers 
(March 2020)
1518 Clinical Research in Cardiology (2020) 109:1511–1521
1 3
indicates that the interventional cardiologists took concerns 
seriously having been raised about the risk of peri-proce-
dural transmission of SARS-CoV-2 between STEMI patients 
and medical staff as well as a further dissemination of the 
disease [8, 21, 22]. It has been assumed that the precautions 
and prioritization when taking care of patients with con-
firmed or possible COVID-19 may prolong treatment times, 
thereby affecting the quality of STEMI treatment [7]. How-
ever, we demonstrate here that these precaution procedures 
did not result in a significant delay in reperfusion therapy.
Other process-relevant and clinically important indicators 
of STEMI care performance were also not impaired, such 
as the proportion of pre-hospital ECG recordings, direct 
transports to the catheterization laboratory bypassing the 
emergency department and the achievement of the guideline-
recommended contact-to-balloon time of less than 90 min. 
These data from Germany are not in line with a recent report 
from a small sample of seven STEMI patients treated in 
Hong Kong during the COVID-19 pandemic, which showed 
dramatic changes in treatment times [7]. A report from Italy 
demonstrated that the cumulative incidence of out-of-hos-
pital cardiac arrest was associated with the cumulative inci-
dence of SARS-CoV-2 infections and that the EMS arrival 
time was increased during the virus outbreak [23].
In the FITT-STEMI programme, feedback mechanisms 
had been successfully implemented to shorten treatment 
times and improve prognosis in STEMI patients in previ-
ous years [2, 17, 18, 24]. Even when the EMS systems and 
the hospitals were faced with the burden of the coronavirus 
pandemic, the pre-established routine pathways in STEMI 
care were maintained throughout the crisis and resulted in a 
stable high proportion of patients achieving the guideline-
recommended 90-min limit from first medical contact to rep-
erfusion. Thus, the successful implementation of the require-
ments for high-standard STEMI treatment already before 
the virus outbreak may have saved the participating FITT-
STEMI centres from significant treatment delays, despite the 
rapidly increasing numbers of infections.
Table 3  Subgroup analysis of key quality indicators for STEMI management in seven FITT-STEMI clinics in the Lower Rhine areal located in a 
hot spot of COVID-19 outbreak during the pandemic as compared to the three preceding March months
Data and patients included are given as numbers or means and percentages or standard errors of the mean including the 95%-confidence interval 
for EMS-transported and PCI-treated STEMI patients with contact-to-balloon times reported equal to or less than 360 min
STEMI patients treated 
in the Lower Rhine area 
(n = 1538)
Patients treated in the 
March month 2017/2018/ 
2019 (n = 141)
Patients treated in 
March month 2020 
(n = 35)
95%-confidence interval P value
Symptom-to-contact time 
(min) (n = 1512)
155.1 ± 6.1 178.1 ± 22.2 105.4 ± 23.1 72.7 [− 17.5; 162.8] 0.113
Duration of EMS at scene 
(n = 1502)
21.8 ± 0.3 22.1 ± 0.9 21.7 ± 2.4 0.3 [− 3.8; 4.5] 0.873
Transport time by EMS 
(n = 1502)
14.7 ± 0.2 15.1 ± 0.7 12.1 ± 1.2 2.97 [0.04; 5.90] 0.047
Contact-to-door time 
(min) (n = 1538)
36.6 ± 0.3 37.5 ± 1.1 33.9 ± 2.5 3.6 [− 1.4; 8.7] 0.190
Door-to-cath time (min) 
(n = 1536)
19.8 ± 1.1 18.2 ± 2.5 23.4 ± 6.0 − 5.2 [− 16.7; 6.3] 0.376
Cath-to-puncture time 
(min) (n = 1533)
13.3 ± 0.2 13.4 ± 0.6 14.0 ± 1.3 − 0.6 [− 3.5; 2.2] 0.657
Puncture-to-balloon (min) 
(n = 1538)
19.0 ± 0.3 17.2 ± 0.7 18.9 ± 1.5 − 1,7 [− 4.8; 1.35] 0.258
Door-to-balloon time 
(min) (n = 1538)
51.1 ± 0.8 48.7 ± 2.5 56.3 ± 6.0 − 7.6 [− 19.2; 4.0] 0.200
Contact-to-balloon time 
(min) (n = 1538)
87.6 ± 0.8 86.3 ± 2.6 90.2 ± 6.3 − 3.9 [− 16.0; 8.2] 0.524
ECG before arrival at the 
hospital (n = 1538)
1474 (95.8%) 132 (93.6%) 33 (94.3%) − 0.6 [− 9.4; 8.0] 0.884
Pre-announcement by 
telephone (n = 1538)
1253 (81.5%) 114 (80.9%) 27 (77.1%) 3.7 [− 11.6; 19.1] 0.623
Emergency department 
bypass (n = 1538)
847 (55.1%) 85 (60.3%) 18 (51.4%) 8.9 [− 9.6; 27.3] 0.341
Contact-to-balloon 
time ≤ 90 min (n = 1538)
991 (64.4%) 91 (64.5%) 22 (62.9%) 1.7 [− 19.5; 16.2] 0.853
Hospital mortality 
(n = 1538)
135 (8.8%) 12 (8.5%) 4 (11.4%) − 2.9 [− 14.4; 8.6] 0.591
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Even clinics confronted with high case numbers of 
SARS-CoV-2-infected patients, such as the hospitals in the 
Lower Rhine area, were capable of maintaining high process 
standards in their routine STEMI management. Our meas-
urements were sensitive enough to detect small changes in 
treatment times, as there was a significant 3-min shortening 
during the virus outbreak from the scene to the hospital, 
which probably reflects the slowdown of traffic at that time, 
thereby promoting road-based transportation. Despite their 
fight against the spread of the virus, the hot-spot hospitals 
in the Heinsberg area preserved their obligations for pro-
tocol-based STEMI care using predefined quality markers 
for timely reperfusion. Therefore, concerns about a limited 
number of interventional cardiologists and expert medical 
personnel available in the catheterization laboratory during 
the outbreak period proved to be unfounded.
When faced by the challenge of SARS-CoV-2-pos-
itive patients or subjects with an unknown viral status, 
some authors reconsidered intravenous thrombolysis as 
an alternative, albeit less effective strategy for coronary 
revascularization [21, 25, 26]. However, our data have indi-
cated that in pre-existing functional STEMI care networks 
the success rate for PCI treatment remains at a high level, 
suggesting that there is no need to recommend fibrinolytic 
therapy and abandon PCI.
Several issues merit consideration in the interpretation 
of the present results from the observational FITT-STEMI 
study. Firstly, the registry-based, cross-sectional nature of 
the FITT-STEMI trial may be susceptible to unmeasured 
confounding and selection bias, such as non-system reasons 
for treatment delays independent of the coronavirus crisis. 
Secondly, other German PCI hospitals, which are not mem-
bers in the FITT-STEMI consortium, may be less privileged 
in their treatment pathways for STEMI patients, because 
they do not receive regular site-specific data assessments on 
treatment times and in-hospital mortality using interactive 
feedback sessions. Therefore, it is formally not possible to 
extrapolate our findings to all German PCI centres. Thirdly, 
we assessed only short-term outcome, as data on long-term 
follow-up are currently not available and the SARS-CoV-2 
outbreak is still not under control. Fourthly, the findings 
from our study conducted in Germany are not applicable 
to STEMI management care systems in other countries, in 
which exclusively paramedics are part of the EMS transpor-
tation teams and not physicians experienced in emergency 
medicine. Thus, our results cannot be generalized to STEMI 
care systems in other countries using different pathways for 
treating their patients.
In summary, during the COVID-19 crisis, we observed 
no impairment in the quality of STEMI care in the Ger-
man FITT-STEMI hospitals. Our data suggest that a pre-
established, robust organisational structure for STEMI care 
is an important requirement for timely treatment of STEMI 
patients and ensures the stability of outcome-relevant per-
formance parameters, even when confronted with the burden 
of the global, ongoing pandemic.
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